<DOC>
	<DOCNO>NCT01326546</DOCNO>
	<brief_summary>The purpose evaluate efficacy safety therapeutic hepatitis B virus ( HBV ) vaccine ( synthesized peptide ) Joint entecavir treatment chronic hepatitis B patient .</brief_summary>
	<brief_title>Therapeutic Hepatitis B Vaccine ( Synthesized Peptide εPA-44 ) Joint Entecavir Treating Chronic Hepatitis B Patients</brief_title>
	<detailed_description>Eligible subject enrol assigned 2 group randomly 1:1 ratio： 1 . Therapeutic HBV vaccine Joint Entecavir group：Inject εPA-44 900μg week 0 , 3 , 6 , 9 , 12 , 15 , 18 , 21 , 24 , 28 , 32 , 36 , 40 , 44 , 48 + Oral intake entecavir 0.5mg per day ； 2 . Empty liposome Joint Entecavir group：Inject empty liposome 900μg week 0 , 3 , 6 , 9 , 12 , 15 , 18 , 21 , 24 , 28 , 32 , 36 , 40 , 44 , 48 + Oral intake entecavir 0.5mg per day . The study cycle consist screen enrollment period ( week -4～0 ) , treatment follow-up period ( week 0-96 ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Aged 1865 year , male female ; 2 . Conforming diagnosis standard chronic hepatitis B accord `` 2005 Guideline Prevention Treatment Hepatitis B `` , ( positive HBsAg 6 month ) , never systemic treatment antiHBV viral , HBVDNA ≥ 1.72×104 IU/ml； HBeAg ( + ) , HBeAb ( ) ； ALT within 2 10 time ULN ( upper limit normal ) ; 3 . HLAA2 positive ; 4 . Compensatory liver disease follow hematological biochemical parameter : WBC ≥ 3.5×109/L ; ANC ≥ 1.5×109/L ; PLT ≥ 80×109/L ; Hb ≥ 100g/L ; TBil ≤ 1.5 ULN ; ALB low low limit normal value ; BUN high limit normal value ; Cr ≤ 1.5 ULN high limit normal value ; PT elongation ≤ 3 sec , APTT normal value ; Fasting blood glucose ≤ 7.0mmol/L ; 5 . TSH normal value ; 6 . AFP test result high limit normal value ; 7 . Take effective contraception subject childbearing potential ( include female female partner male ) ; 8 . Understand sign ICF approve EC ; 9 . Willing comply study procedure complete study . 1 . Antibodies HCV , HDV HIV positive ; 2 . ANA titer ＞ 1:100 ; 3 . Decompensated liver disease ( gullet pylorus varicose vein , hepatic encephalopathy ) ; 4 . Have follow illness severe disease inappropriate participate study view investigator , cardiovascular system : instable significant cardiovascular illness angina pectoris , heart attack myocardial infarction , congestive heart failure , severe hypertension , significant arrhythmia abnormal ECG etc ; Respiratory system : bronchiectasia , bronchial asthma , chronic obstructive pulmonary disease , respiratory failure , etc ; Endocrine , metabolism disease : diabetes mellitus , uncontrolled thyroid disease , etc ; Others : autoimmune disorder , active tuberculosis , malignancy ( e.g . : tumor ) , neuropathic , metal , acute chronic pancreatitis illness history , etc . 5 . Have use antiHBV drug ( Interferon , Lamivudine , Adefovir Dipivoxil , Entecavir Telbivudine ) immunomodulator ( Thymic peptide , etc ) administration study medication ; 6 . Have allergic diathesis suspect allergy εPA44 ; 7 . Female pregnancy , lactation plan pregnancy course study ; 8 . Have history alcohol abuse ( Alcohol consumption 5 year , daily consumption 40g male 20g female ) know drug dependence ; 9 . Have history organ transplantation ( except corneal transplantation hair transplantation ) ; 10 . Have participate drug clinical investigation within 3 month ; 11 . Any factor inappropriate enroll study study completion view investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Therapeutic HBV Vaccine</keyword>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>HBeAg positive</keyword>
</DOC>